These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38515954)

  • 1. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
    Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
    World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors.
    Fan Z; Gong Y; Huang Q; Yang C; Cheng H; Jin K; Fan K; Ni Q; Yu X; Luo G; Liu C
    Pancreas; 2020 Jul; 49(6):751-756. PubMed ID: 32541629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
    Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-center experience with pancreatic cystic neuroendocrine tumors.
    Khalil A; Ewald J; Marchese U; Autret A; Garnier J; Niccoli P; Piana G; Poizat F; Giovannini M; Delpero JR; Turrini O
    World J Surg Oncol; 2020 Aug; 18(1):208. PubMed ID: 32799893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
    Taherifard E; Bakhtiar M; Mahnoor M; Ahmed R; Cavalcante L; Zhang J; Saeed A
    BMC Cancer; 2024 Feb; 24(1):192. PubMed ID: 38347461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Somatostatin Receptor 2 in Nonfunctional Pancreatic Neuroendocrine Tumors: Clinicopathological Analysis of 223 Cases and Whole Exome Sequencing of a Multifocal Case.
    Hu HF; Hu YH; Xu XW; Ye Z; Lou X; Zhang WH; Chen XM; Zhang Y; Yu XJ; Gao HL; Xu JY; Ji SR
    Pancreas; 2022 Nov-Dec 01; 51(10):1404-1410. PubMed ID: 37099786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM.
    Ingenerf M; Karim H; Auernhammer C; Zacherl M; Wenter V; Winkelmann M; Ricke J; Berger F; Schmid-Tannwald C
    Radiol Oncol; 2023 Dec; 57(4):436-445. PubMed ID: 38038419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients.
    Krogh S; Grønbæk H; Knudsen AR; Kissmeyer-Nielsen P; Hummelshøj NE; Dam G
    Front Endocrinol (Lausanne); 2022; 13():925632. PubMed ID: 35837305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place.
    de Mestier L; Gaujoux S; Cros J; Hentic O; Vullierme MP; Couvelard A; Cadiot G; Sauvanet A; Ruszniewski P; Richard S; Hammel P
    Ann Surg; 2015 Aug; 262(2):384-8. PubMed ID: 25185468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision radiotherapy using MR-linac for pancreatic neuroendocrine tumors in MEN1 patients (PRIME): a protocol for a phase I-II trial, and systematic review on available evidence for radiotherapy of pNETs.
    van Vliembergen ENM; Eijkelenkamp H; Valk GD; Vriens MR; Meijer GJ; Intven MPW; de Laat JM
    Front Endocrinol (Lausanne); 2023; 14():994370. PubMed ID: 37305036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrine tumor: A meta-analysis.
    Cen D; Chen J; Li Z; Zhao J; Cai X
    PLoS One; 2017; 12(11):e0187588. PubMed ID: 29136022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation.
    Saleh Z; Moccia MC; Ladd Z; Joneja U; Li Y; Spitz F; Hong YK; Gao T
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
    Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
    J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination and characterization of molecular heterogeneity and precision medicine strategies of patients with pancreatic cancer and pancreatic neuroendocrine tumor based on oxidative stress and mitochondrial dysfunction-related genes.
    Cui Y; Yuan Q; Chen J; Jiang J; Guan H; Zhu R; Li N; Liu W; Wang C
    Front Endocrinol (Lausanne); 2023; 14():1127441. PubMed ID: 37223030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma.
    Kim JH; Eun HW; Kim YJ; Lee JM; Han JK; Choi BI
    Eur Radiol; 2016 May; 26(5):1338-47. PubMed ID: 26253257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling the impact of cancer-associated fibroblasts on hypovascular pancreatic neuroendocrine tumors.
    Lai TY; Chiang TC; Lee CY; Kuo TC; Wu CH; Chen YI; Hu CM; Maskey M; Tang SC; Jeng YM; Tien YW; Lee EYP; Lee WH
    Br J Cancer; 2024 Apr; 130(7):1096-1108. PubMed ID: 38341509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of CT characteristics in GEP-NET: A systematic review.
    van der Velden DL; Staal FCR; Aalbersberg EA; Castagnoli F; Wilthagen E; Beets-Tan RGH
    Crit Rev Oncol Hematol; 2022 Jul; 175():103713. PubMed ID: 35598829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Syndrome Is Associated with Impaired Survival after Surgery for Pancreatic Neuroendocrine Tumors.
    Awwad F; Ozga AK; Amin T; Schlueter C; Kailani S; Perez D; Wolter S; Sauter G; Izbicki J; Lohse AW; Schrader J
    Neuroendocrinology; 2022; 112(12):1225-1236. PubMed ID: 35354139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Nonfunctioning Pancreatic Neuroendocrine Tumors.
    Heidsma CM; van Roessel S; van Dieren S; Engelsman AF; Strobel O; Buechler MW; Schimmack S; Perinel J; Adham M; Deshpande V; Kjaer J; Norlen O; Gill AJ; Samra JS; Mittal A; Hoogwater FJH; Primavesi F; Stättner S; Besselink MG; van Eijck CHJ; Nieveen van Dijkum EJM
    Neuroendocrinology; 2022; 112(6):571-579. PubMed ID: 34343138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of the Regional Lymph Node Station in Pancreatic Neuroendocrine Tumor.
    Takagi K; Umeda Y; Yoshida R; Yoshida K; Fuji T; Kumano K; Yasui K; Yagi T; Fujiwara T
    Anticancer Res; 2022 May; 42(5):2797-2801. PubMed ID: 35489738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.